183 related articles for article (PubMed ID: 32440959)
1. Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer.
Horii R; Tsuda H; Masuda S; Sugita H; Togashi K; Ohno S; Akiyama F
Breast Cancer; 2020 Nov; 27(6):1058-1064. PubMed ID: 32440959
[TBL] [Abstract][Full Text] [Related]
2. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
Morimoto M; Bando Y; Nakagawa M; Takechi H; Yoshida T; Honda J; Tadokoro Y; Moriya T; Sasa M; Tangoku A
Breast Cancer; 2016 Jul; 23(4):577-82. PubMed ID: 25808597
[TBL] [Abstract][Full Text] [Related]
4. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue.
Laurinavicius A; Plancoulaine B; Laurinaviciene A; Herlin P; Meskauskas R; Baltrusaityte I; Besusparis J; Dasevicius D; Elie N; Iqbal Y; Bor C
Breast Cancer Res; 2014; 16(2):R35. PubMed ID: 24708745
[TBL] [Abstract][Full Text] [Related]
5. Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.
Kwon AY; Park HY; Hyeon J; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Cho SY; Cho EY
PLoS One; 2019; 14(2):e0212309. PubMed ID: 30785924
[TBL] [Abstract][Full Text] [Related]
6. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Wang YX; Wang YY; Yang CG; Bu H; Yang WT; Wang L; Xu WM; Zhao XL; Zhao WX; Li L; Song SL; Yang JL
Breast; 2020 Feb; 49():225-232. PubMed ID: 31911370
[TBL] [Abstract][Full Text] [Related]
7. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
8. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.
Arihiro K; Oda M; Ohara M; Kadoya T; Osaki A; Nishisaka T; Shiroma N; Kobayashi Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1081-1087. PubMed ID: 27511992
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
12. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
[TBL] [Abstract][Full Text] [Related]
14. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
15. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma.
Feng M; Deng Y; Yang L; Jing Q; Zhang Z; Xu L; Wei X; Zhou Y; Wu D; Xiang F; Wang Y; Bao J; Bu H
Diagn Pathol; 2020 May; 15(1):65. PubMed ID: 32471471
[TBL] [Abstract][Full Text] [Related]
16. A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.
Alataki A; Zabaglo L; Tovey H; Dodson A; Dowsett M
Histopathology; 2021 Aug; 79(2):200-209. PubMed ID: 33590538
[TBL] [Abstract][Full Text] [Related]
17. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
18. Impact of Primary Antibody Clone, Format, and Stainer Platform on Ki67 Proliferation Indices in Breast Carcinomas.
Røge R; Nielsen S; Riber-Hansen R; Vyberg M
Appl Immunohistochem Mol Morphol; 2019; 27(10):732-739. PubMed ID: 31460869
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant therapy on breast cancer biomarker profile.
Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
[TBL] [Abstract][Full Text] [Related]
20. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Robertson S; Acs B; Lippert M; Hartman J
Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
